Results 241 to 250 of about 84,264 (300)

MicroRNA‐Mediated Regulation of Brain Aging Hallmarks: Implications for Neurodegeneration and Neural Recovery

Brain and Behavior, Volume 16, Issue 5, May 2026.
Hallmarks of brain aging regulated by microRNAs (miRNAs). This graphical abstract illustrates the central role of miRNAs in coordinating key biological processes associated with brain aging. miRNAs regulate multiple interconnected hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis and impaired ...
Mustafa T. Ardah, Pareshkumar N. Patel, Omayma Salim Waleed, Jamuna K. V., Vandana Tripathi, L. Lakshmi, Rajashree Panigrahi, Manoj Kumar Mishra   +7 more
wiley   +1 more source

Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for Their Synthesis

ChemistryEurope, Volume 4, Issue 5, May 2026.
Screening of chemical libraries has over the past decades become a cornerstone of drug discovery. Today, a broad range of chemical libraries exist but they are often not well described in terms of diversity. This review describes current efforts which aim to visualize chemical diversity in compound collections and discuss current trends in synthetic ...
Tobias N. Hansen, Nils J. V. Hansen
wiley   +1 more source

Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 5, May 2026.
Abstract Zampilimab (UCB7858) is a humanized monoclonal immunoglobulin G4P, transglutaminase 2 (TG2) inhibiting antibody. We investigated safety, tolerability, pharmacokinetics, and target occupancy of zampilimab (intravenous ≤2000 mg; subcutaneous ≤1000 mg) in healthy participants in a randomized, placebo‑controlled, single‐ascending‐dose Phase 1 ...
Jo Collier, Rowann Bowcutt, Geoffrey I. Johnston, Jane Y. C. Chan, Anastasiia Raievska, Alison Bigley, Richard Nicholl, Tim S. Schmidt, Maria Sarno, Zahid Ali, Elizabeth Thomson   +10 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase inhibitors

Current Anaesthesia & Critical Care, 1993
Despite the justifiable concern about the use of oral cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitors, the intravenous preparations are clearly effective in the treatment of acute heart failure, whether it occurs de novo or complicating chronic congestive heart failure (CHF), and in low output states following cardiac surgery ...
R, Andrews, A J, Cowley
  +6 more sources

Phosphodiesterase inhibitors and the eye

Clinical & Experimental Ophthalmology, 2009
AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M, Kerr, Helen V, Danesh-Meyer
openaire   +2 more sources

Phosphodiesterase 4 inhibitors

Journal of the American Academy of Dermatology, 2018
Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids and topical calcineurin inhibitors, with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy and infrequent adverse events, phobia about the use of topical steroids and calcineurin inhibitors has limited
Rema, Zebda, Amy S, Paller
openaire   +2 more sources

Electrophysiology of phosphodiesterase inhibitors

The American Journal of Cardiology, 1989
Phosphodiesterase inhibitors appear to uniformly enhance atrioventricular node conduction, although milrinone seems to have the least effect. Except for digoxin, this effect on atrioventricular node conduction is similar to that noted with other inotropic agents.
G V, Naccarelli, R A, Goldstein
openaire   +2 more sources

Xanthines and Phosphodiesterase Inhibitors

2016
Theophylline is an orally acting xanthine that has been used since 1937 for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, in most treatment guidelines, xanthines have now been consigned to third-line therapy because of their narrow therapeutic window and propensity for drug-drug ...
D, Spina, C P, Page
openaire   +2 more sources

In Defense of Phosphodiesterase 5 Inhibitors

JAMA Ophthalmology, 2022
Not ...
Belladelli, Federico, Del Giudice, Francesco, Eisenberg, Michael L   +2 more
openaire   +3 more sources